Organon (OGN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68622V1061

Contraceptives, Fertility medicines, Biosimilars, Oncology products, Cholesterol medicines

Organon & Co is a leading healthcare company that develops and delivers innovative health solutions, focusing primarily on women's health. Its extensive portfolio includes a range of prescription therapies and medical devices that cater to various women's health needs globally.

The company's women's health portfolio boasts an impressive lineup of contraception and fertility brands. These include Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, a combination of progestin and estrogen used as daily pills to prevent pregnancy; and Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures. Additionally, the portfolio includes Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, used to treat abnormal postpartum uterine bleeding or hemorrhage.

Beyond women's health, Organon & Co has a robust biosimilars portfolio, featuring immunology products such as Brenzys, Renflexis, and Hadlima. The company also offers two oncology products, including Ontruzant and Aybintio. Furthermore, its portfolio includes cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands.

The company's product range extends to treatments for hypertension, such as Cozaar and Hyzaar. It also offers respiratory products, including Singulair, Dulera, Zenhale, and Asmanex, which help control and prevent symptoms caused by asthma. For seasonal allergic rhinitis, the company provides Singulair, Nasonex, Clarinex, and Aerius.

Organon & Co's dermatology portfolio includes Diprosone and Elocon brands, while its bone health portfolio features the Fosamax brand name. The company also offers non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names. Furthermore, it provides Proscar for the treatment of symptomatic benign prostatic hyperplasia and Propecia for the treatment of male pattern hair loss.

Organon & Co sells its products to a wide range of customers, including drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Headquartered in Jersey City, New Jersey, the company was incorporated in 2020 and is committed to improving healthcare outcomes globally. For more information, visit

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Organon (OGN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Organon (OGN) - Stock Price & Dividends

OGN Stock Overview

Market Cap in USD 5,458m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2021-06-02

OGN Stock Ratings

Growth 5y -2.83
Fundamental -4.79
Dividend 5.32
Rel. Performance vs Sector -0.03
Analysts 3.44/5
Fair Price Momentum 23.89 USD
Fair Price DCF 54.14 USD

OGN Dividends

Yield 12m 5.34%
Yield on Cost 5y 3.89%
Dividends CAGR 5y 0.00%
Payout Consistency 99.3%

OGN Growth Ratios

Growth 12m 16.31%
Growth Correlation 12m -5%
Growth Correlation 3m 59%
CAGR 5y -9.88%
CAGR/Mean DD 5y -0.32
Sharpe Ratio 12m 0.26
Alpha vs SP500 12m -7.57
Beta vs SP500 5y weekly 0.82
ValueRay RSI 59.58
Volatility GJR Garch 1y 32.71%
Price / SMA 50 10.48%
Price / SMA 200 26.69%
Current Volume 1190.9k
Average Volume 20d 2097.6k

External Links for OGN Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of OGN stocks?
As of May 30, 2024, the stock is trading at USD 20.98 with a total of 1,190,903 shares traded.
Over the past week, the price has changed by -3.98%, over one month by +12.54%, over three months by +19.30% and over the past year by +16.31%.
What are the forecast for OGN stock price target?
According to ValueRays Forecast Model, OGN Organon will be worth about 25.8 in May 2025. The stock is currently trading at 20.98. This means that the stock has a potential upside of +22.97%.
Issuer Forecast Upside
Wallstreet Target Price 22.5 7.24
Analysts Target Price 29.3 39.6
ValueRay Target Price 25.8 23.0